弥漫大B细胞淋巴瘤患者临床特征及预后分析

赵洁, 姜言, 郝思国

Clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma

ZHAO Jie, JIANG Yan, HAO Siguo

表5 复发/难治性DLBCL患者死亡的危险因素分析

Tab 5 Risk factor analysis for death in patients with relapsed/refractory DLBCL

Variable Death rate Patients/n(%) P value Gender Male 23/35 (65.7) 0.570 Female 11/19 (57.9) Age ≤60 years 9/16 (56.3) 0.507 >60 years 25/38 (65.8) Group B symptoms No 17/25 (68.0) 0.477 Yes 17/29 (58.6) Hans classification GCB 8/10 (80.0) 0.383 Non-GCB 26/44 (59.1) ECOG score <2 scores 20/31 (64.5) 0.784 ≥2 scores 14/23 (60.9) Ann Arbor stage Ⅰ‒Ⅱ 8/12 (66.7) 1.000 Ⅲ‒Ⅳ 26/42 (61.9) IPI score 0‒2 scores 7/12 (58.3) 0.970 3‒5 scores 27/42 (64.3) LDH level ≤211 U·L-1 4/8 (50.0) 0.670 >211 U·L-1 30/46 (65.2) Albumin level ≥35 g·L-1 20/32 (62.5) 0.932 <35 g·L-1 14/22 (63.6) Absolute lymphocyte level >1.1×109·L-1 19/27 (70.4) 0.260 ≤1.1×109·L-1 15/27 (55.6) Anemia No 19/29 (65.5) 0.675 Yes 15/25 (60.0) ASCT Yes 0/4 (0) 0.030 No 34/50 (68.0)